Medical device and MedTech insights, news, tips and more

Emails That Land Jobs: The Best Way to Shine in a Follow-Up Note

March 28, 2016

Emails

110. That’s how many emails most “working professionals” send and receive every day.

The bad news? That’s a whole lot of noise—and it can feel difficult to pop out from the pile, especially when you’re trying to lock down a new job opportunity.

The good news? Most emails are poorly written, awkward, vague, or just plain boring. And when 99% of the incoming stream is blah-blah-beige, it doesn’t take too much effort to shine brighter than a disco ball.

EmailsSo, what’s the best way to shine?

Simple: Be unexpectedly generous.

A quick story: A few years ago, I was courting a local marketing agency for a freelance copywriting position. I’d done a bit of copywriting for my previous employer, but the truth was, I didn’t have much of a portfolio to back up my skills.

After my informal interview, the director of the marketing agency told me:

“We like your spirit, but we just can’t hire you without seeing a few more writing samples.”

We shook hands and parted ways. I felt deflated, like I was a total rookie—a nobody.

But then, I had a life-changing light bulb moment. They wanted samples—I’d show ’em samples.

In fact, I’d do more than that—I’d send over some ready-to-use language for their soon-to-be-re-launched website, as if I was already part of the team.

I wrote a quick email to the very, very busy agency director, thanking her for taking the time to meet with me. And, oh, by the way:

“Here are 10 tagline options to consider as you revamp your brand. No charge. Enjoy!”

The director wrote back to say:

“These taglines are better than anything we’ve come up with on our own. Thank you. Let’s set up a meeting so you can get started on writing the rest of our site content.”

Read More – Source: Emails That Land Jobs: The Best Way to Shine in a Follow-Up Note

By Alexandra Franzen

More insights

November 11, 2024
What is the Difference Between MedTech and TechMed?  
Learn More
March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.